153 related articles for article (PubMed ID: 12171729)
1. CAMPATH-1M T-cell depleted BMT for SCID: long-term follow-up of 19 children treated 1987-98 in a single center.
Gennery AR; Dickinson AM; Brigham K; Barge D; Spickett GP; Curtis A; Spencer V; Jackson A; Cavanagh G; Carter V; Palmer P; Flood TJ; Cant AJ; Abinun M
Cytotherapy; 2001; 3(3):221-32. PubMed ID: 12171729
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
[TBL] [Abstract][Full Text] [Related]
3. Infectious complications following T-cell depleted hematopoietic stem-cell transplantation.
Novitzky N; Rouskova A
Cytotherapy; 2001; 3(3):165-73. PubMed ID: 12171723
[TBL] [Abstract][Full Text] [Related]
4. Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation.
Dror Y; Gallagher R; Wara DW; Colombe BW; Merino A; Benkerrou M; Cowan MJ
Blood; 1993 Apr; 81(8):2021-30. PubMed ID: 8471764
[TBL] [Abstract][Full Text] [Related]
5. CAMPATH-1 antibodies in stem-cell transplantation.
Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
[TBL] [Abstract][Full Text] [Related]
6. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients.
Haddad E; Landais P; Friedrich W; Gerritsen B; Cavazzana-Calvo M; Morgan G; Bertrand Y; Fasth A; Porta F; Cant A; Espanol T; Müller S; Veys P; Vossen J; Fischer A
Blood; 1998 May; 91(10):3646-53. PubMed ID: 9573000
[TBL] [Abstract][Full Text] [Related]
7. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
[TBL] [Abstract][Full Text] [Related]
8. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the european society for immunodeficiency.
Bertrand Y; Landais P; Friedrich W; Gerritsen B; Morgan G; Fasth A; Cavazzana-Calvo M; Porta F; Cant A; Espanol T; Müller S; Veys P; Vossen J; Haddad E; Fischer A
J Pediatr; 1999 Jun; 134(6):740-8. PubMed ID: 10356144
[TBL] [Abstract][Full Text] [Related]
9. In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID).
Dickinson AM; Reid MM; Abinun M; Peak J; Brigham K; Dunn J; Cant AJ
Bone Marrow Transplant; 1997 Feb; 19(4):323-9. PubMed ID: 9051241
[TBL] [Abstract][Full Text] [Related]
10. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation.
Cavazzana-Calvo M; Bensoussan D; Jabado N; Haddad E; Yvon E; Moskwa M; Tachet des Combes A; Buisson M; Morand P; Virion JM; Le Deist F; Fischer A
Br J Haematol; 1998 Nov; 103(2):543-51. PubMed ID: 9827933
[TBL] [Abstract][Full Text] [Related]
11. T cell depleted haploidentical bone marrow transplantation for the treatment of children with severe combined immunodeficiency.
Smogorzewska EM; Brooks J; Annett G; Kapoor N; Crooks GM; Kohn DB; Parkman R; Weinberg KI
Arch Immunol Ther Exp (Warsz); 2000; 48(2):111-8. PubMed ID: 10807052
[TBL] [Abstract][Full Text] [Related]
12. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
Naparstek E; Delukina M; Or R; Nagler A; Kapelushnik J; Varadi G; Strauss N; Cividalli G; Aker M; Brautbar C; Waldmann H; Hale G; Slavin S
Exp Hematol; 1999 Jul; 27(7):1210-8. PubMed ID: 10390197
[TBL] [Abstract][Full Text] [Related]
13. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia.
Lowdell MW; Craston R; Ray N; Koh M; Galatowicz G; Prentice HG
Bone Marrow Transplant; 1998 Apr; 21(7):679-86. PubMed ID: 9578307
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center.
Ozsahin H; Le Deist F; Benkerrou M; Cavazzana-Calvo M; Gomez L; Griscelli C; Blanche S; Fischer A
J Pediatr; 1996 Aug; 129(2):238-44. PubMed ID: 8765621
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of CAMPATH-1H in BMT patients.
Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
[TBL] [Abstract][Full Text] [Related]
17. HLA non-identical T-cell-depleted bone marrow transplantation for primary immunodeficiency diseases.
Giri N; Vowels M; Ziegler JB; Ford D; Lam-Po-Tang R
Aust N Z J Med; 1994 Feb; 24(1):26-30. PubMed ID: 8002854
[TBL] [Abstract][Full Text] [Related]
18. Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: A single-center study of 22 patients.
Haddad E; Le Deist F; Aucouturier P; Cavazzana-Calvo M; Blanche S; De Saint Basile G; Fischer A
Blood; 1999 Oct; 94(8):2923-30. PubMed ID: 10515898
[TBL] [Abstract][Full Text] [Related]
19. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
[TBL] [Abstract][Full Text] [Related]
20. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
